retrospect
review
patient
sever
combin
immunodefici
pneumocysti
jirovecii
pneumonia
pcp
evalu
relationship
durat
therapi
treat
pcp
overal
surviv
found
patient
receiv
day
antibiot
surviv
month
beyond
hematopoet
cell
transplant
wherea
patient
requir
longer
treatment
pcp
surviv
stem
cell
engraft
pneumocysti
jirovecii
pneumonia
pcp
common
present
respiratori
ill
infant
sever
combin
immunodefici
scid
prior
studi
report
children
newli
diagnos
scid
present
pcp
current
consensu
exist
medic
literatur
regard
ideal
durat
antimicrobi
therapi
treatment
pcp
patient
scid
treatment
durat
vari
day
report
gener
thought
base
experi
hivinfect
children
day
antibiot
effect
clinic
resolut
studi
examin
cohort
infant
treat
pcp
set
newli
diagnos
scid
assess
relationship
durat
therapi
pcp
clinic
outcom
conduct
retrospect
review
patient
scid
identifi
code
crossreferenc
physician
kept
record
treat
seattl
children
hospit
includ
subject
proven
pcp
complet
document
treatment
cours
approv
studi
obtain
seattl
children
institut
review
board
standard
microbiolog
techniqu
use
conduct
fluoresc
stain
bronchoalveolar
lavag
bal
nasal
wash
specimen
pneumocysti
jirovecii
use
monoclon
antibodi
biorad
california
visual
cyst
constitut
posit
test
viral
pathogen
detect
use
direct
fluoresc
antigen
fa
detect
millipor
massachusett
mp
biomed
california
cultur
nasal
wash
bal
specimen
virus
detect
fa
cultur
includ
respiratori
syncyti
viru
rsv
influenza
b
parainfluenza
virus
piv
human
metapneumoviru
hmpv
sinc
adenoviru
addit
respiratori
viru
polymeras
chain
reaction
pcr
util
begin
detect
rsv
influenza
b
piv
hmpv
rhinoviru
adenoviru
coronaviru
bocaviru
sinc
diagnosi
scid
determin
immunolog
test
includ
quantit
immunoglobulin
lymphocyt
subset
analysi
phytohemagglutinin
stimul
cell
flow
cytometri
gene
sequenc
use
character
specif
form
scid
gather
data
demograph
diagnosi
p
jirovecii
antibiot
dosag
durat
corticosteroid
use
durat
maximum
ventilatori
support
age
scid
present
hct
death
end
studi
period
scid
phenotyp
genotyp
known
addit
respiratori
pathogen
infect
primari
outcom
measur
surviv
engraft
follow
hct
secondari
outcom
resolut
respiratori
symptom
surviv
posthct
period
patient
scid
identifi
facil
suspect
pcp
proven
pneumocysti
jirovecii
recov
clinic
respiratori
specimen
one
patient
incomplet
record
therefor
analysi
includ
patient
scid
proven
pcp
welldocu
treatment
cours
overal
patient
male
caucasian
one
patient
africanamerican
hispan
asian
median
age
present
month
seven
infant
respiratori
viral
copathogen
detect
prehct
period
see
tabl
patient
receiv
corticosteroid
five
nine
patient
pcp
receiv
treatment
tmpsmx
day
case
four
patient
display
clinic
resolut
respiratori
symptom
respiratori
relaps
went
hct
without
need
supplement
oxygen
surviv
month
posthct
four
patient
seri
receiv
day
tmpsmx
case
decis
treat
longer
govern
presenc
continu
tachypnea
hypoxemia
document
persist
organ
despit
day
initi
tmp
smx
therapi
two
patient
repeat
bal
test
end
treatment
cours
document
pcp
clearanc
three
patient
also
signific
respiratori
viral
copathogen
identifi
bal
specimen
pcp
resolut
hmpv
parainfluenza
rsv
three
surviv
engraft
follow
hct
primari
outcom
measur
surviv
engraft
follow
hct
children
requir
greater
day
antimicrobi
therapi
clinic
resolut
surviv
engraft
wherea
patient
receiv
day
cours
surviv
engraft
follow
hct
cohort
infant
scid
pcp
account
present
ill
children
abl
clinic
resolv
infect
day
cours
tmpsmx
observ
associ
protract
cours
pcp
decreas
surviv
engraft
follow
hct
may
relat
subsequ
respiratori
viru
infect
knowledg
first
studi
demonstr
associ
seri
patient
requir
day
treatment
erad
pcp
studi
illustr
import
observ
bal
repeat
respiratori
symptom
persist
standard
period
therapi
assess
residu
infect
pneumocysti
addit
pathogen
two
patient
receiv
altern
antimicrobi
base
clinic
impress
poor
respons
initi
therapi
desir
avoid
myelosuppress
hct
tmpsmx
remain
best
studi
recommend
agent
pneumocysti
prospect
data
avail
patient
scid
assist
decis
chang
therapeut
agent
although
link
mutat
dihydroptero
synthas
sulfonamid
resist
pneumocysti
found
hiv
infect
patient
receiv
tmpsmx
prophylaxi
clinic
signific
find
remain
controversi
resist
test
avail
cohort
highli
unlik
distinct
popul
receiv
prophylaxi
present
persist
detect
p
jirovecii
document
hiv
posit
adult
asymptomat
follow
day
treatment
thu
complet
exclud
possibl
coincident
shed
sampl
infant
scid
posit
fa
p
jirovecii
followup
bal
correl
ongo
symptom
vulner
patient
popul
lack
function
immun
system
pathogen
load
pcp
detect
immunofluoresc
could
potenti
serv
clue
rel
contribut
symptomatolog
even
small
amount
pneumocysti
regard
pathogen
symptomat
patient
warrant
treatment
optim
overal
outcom
method
detect
respiratori
virus
consist
larg
fa
cultur
less
sensit
respiratori
pcr
panel
use
institut
today
virus
detect
pcr
rhinoviru
bocaviru
extens
studi
children
primari
immunodefici
role
lower
respiratori
tract
infect
patient
scid
wellcharacter
rhinoviru
may
respons
lower
respiratori
tract
infect
transplant
popul
howev
asymptomat
shed
also
common
studi
everi
patient
scid
diagnos
sinc
least
one
viru
detect
pcr
lower
respiratori
tract
studi
clearli
demonstr
presenc
lower
tract
virus
preclud
coinfect
pcp
result
suggest
persist
pcp
beyond
week
therapi
may
correl
wors
outcom
overal
specif
higher
risk
die
respiratori
caus
achiev
engraft
follow
hct
number
small
assert
find
absolut
certainti
studi
adult
hiv
demonstr
residu
perman
pulmonari
dysfunct
follow
pcp
infect
pcp
infect
scid
mice
regul
product
surfact
protein
b
c
therebi
contribut
sever
respiratori
compromis
potenti
render
lung
vulner
secondari
infect
respiratori
virus
also
case
infant
scid
treatment
pcp
achiev
erad
complet
clinic
resolut
symptom
paramount
regard
specif
scid
phenotyp
four
infant
phenotyp
evenli
distribut
two
treatment
durat
group
clear
pattern
tbnk
cell
statu
emerg
could
explain
differ
outcom
pcp
overal
surviv
limit
studi
includ
small
sampl
size
retrospect
design
scid
rare
disord
make
prospect
studi
impract
institut
draw
larg
referr
base
mani
year
experi
enabl
us
studi
cohort
infant
specif
infect
context
rare
primari
immunodefici
spite
inher
limit
studi
repres
first
look
treatment
durat
outcom
infant
scid
present
pcp
larger
multicent
collabor
studi
need
evalu
associ
persist
pcp
decreas
overal
surviv
found
studi
